Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571320 | 0.93 | CTSK (0.36) | CTSKMEN1MAPK1KMT2ACTSL | |
| SCHEMBL76972 | 0.93 | CTSK (0.36) | CTSKMEN1MAPK1KMT2ACTSL | |
| SCHEMBL8284389 | 0.91 | CTSK (0.36) | CTSKMEN1MAPK1KMT2ACTSL | |
| SCHEMBL1666805 | 0.88 | USP2 (0.37) | CTSKMEN1MAPK1KMT2ACTSL | |
| SCHEMBL21505983 | 0.88 | MEN1 (0.37) | CTSKMEN1MAPK1KMT2ACTSL | |
| SCHEMBL22079845 | 0.87 | HCRTR2 (0.33) | CTSKMEN1MAPK1KMT2A | |
| SCHEMBL22380385 | 0.85 | CTSK (0.33) | CTSKMEN1MAPK1KMT2ACTSL | |
| SCHEMBL28421186 | 0.84 | USP2 (0.44) | — | |
| SCHEMBL23007977 | 0.84 | GAA (0.39) | CTSKMEN1MAPK1KMT2AAPLNR | |
| SCHEMBL21119394 | 0.83 | CTSK (0.33) | CTSKMEN1MAPK1KMT2ACTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA AS (DK) | 2026-02-19 | — | — | US | disclosed |
| US-20260042788-A1 | STAT6 COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250326767-A1 | NOVEL BENZOTHIAZOLE DERIVATIVES | CARNA BIOSCIENCES, INC. (JP) | 2025-10-23 | — | — | US | disclosed |
| US-12421249-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-09-23 | — | — | US | disclosed |
| US-12391644-B2 | Potassium channel inhibitors | SANIONA A/S (DK) | 2025-08-19 | — | — | US | disclosed |
| EP-3941903-B1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA AS (DK) | 2025-07-16 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-5380874-A | Pyrrolidine carbamates | DAIICHI SEIYAKU CO., LTD. (JP) | 1995-01-10 | — | — | US | disclosed |
| EP-0207420-B1 | PYRIDONECARBOXYLIC ACID DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1992-05-06 | — | — | EP | disclosed |
| US-5098912-A | Bactericides for grampositive bacteria | DAIICHI SEIYAKU CO., LTD. (JP) | 1992-03-24 | — | — | US | disclosed |
| US-4701552-A | ARTIFICIAL SWEETENERS | GENERAL FOODS CORPORATION (US) | 1987-10-20 | — | — | US | disclosed |
| US-4678675-A | Sweetening with L-aminodicarboxylic acid alkenes | GENERAL FOODS CORPORATION (US) | 1987-07-07 | — | — | US | disclosed |
| US-4652676-A | L-aminodicarboxylic acid alkenes | GENERAL FOODS CORPORATION (US) | 1987-03-24 | — | — | US | disclosed |
| EP-0201844-A1 | L-Aminodicarboxylic acid alkenes and an edible composition containing same | GENERAL FOODS CORPORATION (US) | 1986-11-20 | — | — | EP | disclosed |
| EP-0201077-A1 | L-Aminodicarboxylic acid alkanes and an edible composition containing same | GENERAL FOODS CORPORATION (US) | 1986-11-12 | — | — | EP | disclosed |
| US-4622232-A | L-aminodicarboxylic acid alkanes | GENERAL FOODS CORPORATION (US) | 1986-11-11 | — | — | US | disclosed |
| US-4603012-A | L-aminodicarboxylic acid alkanes | GENERAL FOODS CORPORATION (US) | 1986-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042788-A1 | STAT6 COMPOUNDS | STAT6, IL6ST, NFATC1 | CTSK 2215/4885MEN1 4198/4885MAPK1 250/4885 |
| US-12421249-B2 | Inhibitors of APOL1 and methods of using same | APOL1, PNLIP, APOB | CTSK 575/4885MEN1 1732/4885MAPK1 1799/4885 |
| US-12391644-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | CTSK 819/4885MEN1 2574/4885MAPK1 1084/4885 |
| US-20250326767-A1 | NOVEL BENZOTHIAZOLE DERIVATIVES | DYRK1A, DYRK4, DYRK2 | CTSK 77/4885MEN1 3165/4885MAPK1 609/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | CTSK 2087/4885MEN1 3270/4885MAPK1 2568/4885 |
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SCN10A, KCNK10, KCNJ2 | CTSK 969/4885MEN1 2323/4885MAPK1 765/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | CTSK 2842/4885MEN1 1386/4885MAPK1 576/4885 |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SCTR, SSTR1, NPY1R | CTSK 1920/4885MEN1 465/4885MAPK1 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.